Protalix Biotherapeutics (NYSE: PLX) net income
Protalix Biotherapeutics reported a net loss of $6.6m for fiscal 2025; in fiscal 2024 it reported a net profit of $2.9m. Earnings per share were −$0.08.
Protalix Biotherapeutics's net income has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2024, −64.7%. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$6.6m | −325.2% | −12.5% | −$0.08 |
| 2024 | $2.9m | −64.7% | 5.5% | $0.04 |
| 2023 | $8.3m | — | 12.7% | $0.12 |
| 2022 | −$14.9m | — | −31.3% | −$0.31 |
| 2021 | −$27.6m | — | −71.9% | −$0.62 |
| 2020 | −$6.5m | — | −10.4% | −$0.22 |
| 2019 | −$18.3m | — | −33.4% | −$1.23 |
| 2018 | −$26.5m | — | −77.3% | — |
| 2017 | −$83.4m | — | −395.9% | — |
| 2016 | −$29.4m | — | −319.2% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Protalix Biotherapeutics net income compared with its sector
By net income for its latest fiscal year, Protalix Biotherapeutics ranks 185th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Protalix Biotherapeutics, −12.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 183rd | Akebia Therapeutics | −$5.3m | −2.3% |
| 184th | Assembly Biosciences | −$6.1m | −8.5% |
| 185th | Protalix Biotherapeutics | −$6.6m | −12.5% |
| 186th | Stoke Therapeutics | −$6.9m | −3.7% |
| 187th | Neogen | −$7.9m | −0.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Protalix Biotherapeutics
- How much did Protalix Biotherapeutics earn in fiscal 2025?
- Protalix Biotherapeutics reported a net loss of $6.6m for fiscal 2025. In fiscal 2024 it reported a net profit of $2.9m.
- What are the earnings per share of Protalix Biotherapeutics?
- They were −$0.08 in fiscal 2025, compared with $0.04 in fiscal 2024.
- What was the most profitable year for Protalix Biotherapeutics?
- Of its last 10 fiscal years, fiscal 2023, with $8.3m.
- Where does Protalix Biotherapeutics rank in its sector by net income?
- It ranks 185th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Protalix Biotherapeutics come from?
- From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Protalix Biotherapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Protalix Biotherapeutics: the Protalix Biotherapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.